Age-related macular degeneration is a multifactorial, polyetiological condition, affecting individuals over the age of 50, primarily characterized by progressive and irreversible loss of central vision. In the pursuit of a deeper understanding of its etiopathogenesis, risk factors, associated biomarkers, and diagnostic metabolites, the omics approach plays an essential role. The primary objective of this study was to evaluate selected omics biomarkers along with hematological and clinical data and to establish their correlations with macular degeneration.